Scientists map immune landscape of liver tumors to predict cancer return
NCT ID NCT07564908
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 64 patients with colorectal cancer that spread to the liver and was surgically removed. Researchers are analyzing tumor samples to see how different immune cells and growth patterns relate to survival and cancer recurrence. The goal is to better understand why some patients do better than others.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors better predict outcomes and tailor treatments for colorectal cancer that has spread to the liver.
- What could go wrong
- This is an observational study analyzing tissue samples, not testing a new treatment. It may not lead to direct patient benefits or changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Peer power: could community education boost cancer screening?
- AI eye for colonoscopy: could software catch what doctors miss?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Could a smartphone photo of stool help detect colon cancer?
- Liver tumors targeted directly: old pump, new drug